Hansoh Pharmaceutical's (HKG:3692) biologics license application for HS-20093 for injection was accepted by China's National Medical Products Administration.
The drug is for the treatment of adult patients with small cell lung cancer, according to a Wednesday Hong Kong bourse filing.